NCT02211690View on ClinicalTrials.gov

The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis

PHASE4CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

November 30, 2015

Study Completion Date

February 29, 2016

Conditions

Human Immunodeficiency Virus

Interventions

DRUG

dolutegravir 50 mg (one tablet daily)

DRUG

emtricitabine-tenofovir 300/200 mg (one tablet daily)

Trial Locations (5)

2000

Sydney Sexual Health Centre, Sydney

2010

St Vincent's Hospital Centre for Applied Medical Research, Darlinghurst

2065

Clinic 16, Royal North Shore Hospital, Sydney

3004

Alfred Hospital, Melbourne

3053

Melbourne Sexual Health Centre, Carlton

All Listed Sponsors

collaborator

ViiV Healthcare Australia Pty. Ltd

UNKNOWN

lead

Andrew Carr

OTHER

NCT02211690 - The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis | Biotech Hunter | Biotech Hunter